Oxford Nanopore Technologies (LON:ONT) used its FY 2025 results call to outline a leadership transition, review a year of growth and cost control, and provide guidance for 2026 alongside commentary on ...
Shares in Oxford Nanopore Technologies fell sharply in morning trading on Monday, after the FTSE 250 firm lowered its ...
The 2026 revenue guidance reflects a deliberate slowdown in its largest region. EMEAI, which grew 26.3% at constant currency ...
Oxford Nanopore Technologies shares fell nearly 12% as the UK biotech firm cut its medium-term revenue growth target, impacting the stock price.
Looking ahead, Oxford Nanopore said for 2026 it expects revenue to grow by between 21% and 25% on a constant currency basis. Back in September, the firm guided for over 30% revenue growth between 2024 ...
OXFORD, England, & LOS ANGELES--(BUSINESS WIRE)--Oxford Nanopore Technologies, the company behind a new generation of molecular sensing technology based on nanopores, and Plasmidsaurus, the LA-based ...
Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks The latest announcement is out from ...
OXFORD, England--(BUSINESS WIRE)--Oxford Nanopore Technologies, the company delivering a new generation of nanopore-based molecular sensing technology, today announced a new collaboration with UK ...
Good morning, and welcome to our 2024 Half Year Interim Results Presentation. I'm Gordon Sanghera, Chief Executive of Oxford Nanopore, and I'm joined today by our CFO, Nick Keher. Today, we will talk ...
The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...
Since the announcement, Bio-Techne’s shares have dipped 0.9%, closing at $61.19 in yesterday’s session. Asuragen brand is well known for its designed, high-quality molecular diagnostic products. The ...
Shares in Oxford Nanopore Technologies fell nearly 12% on Monday after the British biotech firm lowered its medium-term revenue growth target.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results